Stricken Endo Eyes $6bn Debt Cut With Bankruptcy Filing And Restructuring
As Company Pens Nationwide Agreement-In-Principle To Settle US Opioid Claims
Executive Summary
A group of Endo debtholders are looking to buy the firm out of bankruptcy, with an initial $6bn bid for the stricken firm that envisions setting aside more than half-a-billion dollars for opioid-related claims. Meanwhile, Endo has reached an agreement-in-principle to resolve opioid-related claims.
You may also be interested in...
Finance Watch: Third Harmonic Attempts A Flight Through The IPO Window
Public Company Edition: Third Harmonic hopes to double its money, raising up to $150m. Also, Halozyme priced a $625m note sale to retire debt and repurchase shares, while Viridian raised $270m in an offering after positive early data, and Clarus cut jobs while Endo finalized a restructuring plan.
Eagle Vindicated On Vasopressin With US Federal Circuit Decision
Endo’s woes show no sign of abating, with the US Court of Appeals for the Federal Circuit shooting down its appeal against a finding of non-infringement for two key patents shielding its Vasostrict injectable.
Multiple Vasostrict ANDAs Rival Eagle In Competitive Market
Amphastar, Amneal and Aurobindo are among ANDA sponsors confirming USFDA approval for generic versions of Endo’s Vasostrict (vasopressin) 20 units/ml single-dose vial – as first mover Eagle Pharmaceuticals remains locked in patent-litigation proceedings with the originator.